Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

150 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The complement system drives local inflammatory tissue priming by metabolic reprogramming of synovial fibroblasts.
Friščić J, Böttcher M, Reinwald C, Bruns H, Wirth B, Popp SJ, Walker KI, Ackermann JA, Chen X, Turner J, Zhu H, Seyler L, Euler M, Kirchner P, Krüger R, Ekici AB, Major T, Aust O, Weidner D, Fischer A, Andes FT, Stanojevic Z, Trajkovic V, Herrmann M, Korb-Pap A, Wank I, Hess A, Winter J, Wixler V, Distler J, Steiner G, Kiener HP, Frey B, Kling L, Raza K, Frey S, Kleyer A, Bäuerle T, Hughes TR, Grüneboom A, Steffen U, Krönke G, Croft AP, Filer A, Köhl J, Klein K, Buckley CD, Schett G, Mougiakakos D, Hoffmann MH. Friščić J, et al. Among authors: mougiakakos d. Immunity. 2021 May 11;54(5):1002-1021.e10. doi: 10.1016/j.immuni.2021.03.003. Epub 2021 Mar 23. Immunity. 2021. PMID: 33761330 Free article.
Treatment intensification might not improve survival in high-grade B-cell lymphoma with a concurrent MYC and BCL2 and/or BCL6 rearrangement: A retrospective, multicenter, pooled analysis.
Zeremski V, McPhail ED, Habermann TM, Schieppati F, Gebauer N, Vassilakopoulos TP, Mougiakakos D. Zeremski V, et al. Among authors: mougiakakos d. Hematol Oncol. 2023 Oct;41(4):776-780. doi: 10.1002/hon.3130. Epub 2023 Mar 21. Hematol Oncol. 2023. PMID: 36945194 No abstract available.
Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study.
Schubert ML, Bethge WA, Ayuk FA, von Bonin M, Vucinic V, Wagner-Drouet EM, Subklewe M, Baldus CD, Glass B, Marks R, Mougiakakos D, Schroers R, Stelljes M, Topp MS, Wulf G, Kröger N, Dreger P. Schubert ML, et al. Among authors: mougiakakos d. Blood Adv. 2023 Oct 24;7(20):6191-6195. doi: 10.1182/bloodadvances.2023011203. Blood Adv. 2023. PMID: 37603595 Free PMC article. No abstract available.
Impact of FLT3-ITD location on cytarabine sensitivity in AML: a network-based approach.
Pugliese GM, Venafra V, Bica V, Massacci G, Latini S, Graziosi S, Fischer T, Mougiakakos D, Boettcher M, Perfetto L, Sacco F. Pugliese GM, et al. Among authors: mougiakakos d. Leukemia. 2023 May;37(5):1151-1155. doi: 10.1038/s41375-023-01881-5. Epub 2023 Mar 25. Leukemia. 2023. PMID: 36966261 Free PMC article. No abstract available.
Vitamin D-dependent induction of cathelicidin in human macrophages results in cytotoxicity against high-grade B cell lymphoma.
Bruns H, Büttner M, Fabri M, Mougiakakos D, Bittenbring JT, Hoffmann MH, Beier F, Pasemann S, Jitschin R, Hofmann AD, Neumann F, Daniel C, Maurberger A, Kempkes B, Amann K, Mackensen A, Gerbitz A. Bruns H, et al. Among authors: mougiakakos d. Sci Transl Med. 2015 Apr 8;7(282):282ra47. doi: 10.1126/scitranslmed.aaa3230. Sci Transl Med. 2015. PMID: 25855493
PD-L1/PD-1: new kid on the "immune metabolic" block.
Qorraj M, Böttcher M, Mougiakakos D. Qorraj M, et al. Among authors: mougiakakos d. Oncotarget. 2017 Sep 5;8(43):73364-73365. doi: 10.18632/oncotarget.20639. eCollection 2017 Sep 26. Oncotarget. 2017. PMID: 29088710 Free PMC article. No abstract available.
150 results